Under a Trump administration proposal, state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover weight loss drugs Ozempic, Wegovy, Mounjaro and Zepbound for “weight management” purposes, Paige Winfield Cunningham of Washington Post reports, citing Centers for Medicare and Medicaid Services documents obtained by the paper. Ozempic and Wegovy are produced by Novo Nordisk (NVO) while Mounjaro and Zepbound are made by Eli Lilly (LLY). The experiment is expected to start in April 2026 for Medicaid and January 2027 for Medicare plans ,according to the documents.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings Projections
- Eli Lilly (LLY) Bulls Prepare for Multiyear Upside
- Trump posts letters calling on drug company CEOs to lower prices
- Press Secretary says Trump sent letters today to pharmaceutical companies
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!